85 reports of this reaction
1.7% of all CEFUROXIME SODIUM reports
#11 most reported adverse reaction
PULMONARY FIBROSIS is the #11 most commonly reported adverse reaction for CEFUROXIME SODIUM. There are 85 FDA adverse event reports linking CEFUROXIME SODIUM to PULMONARY FIBROSIS. This represents approximately 1.7% of all 5,150 adverse event reports for this drug.
Patients taking CEFUROXIME SODIUM who experience pulmonary fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY FIBROSIS is a less commonly reported adverse event for CEFUROXIME SODIUM, but still significant enough to appear in the safety profile.
In addition to pulmonary fibrosis, the following adverse reactions have been reported for CEFUROXIME SODIUM:
The following drugs have also been linked to pulmonary fibrosis in FDA adverse event reports:
PULMONARY FIBROSIS has been reported as an adverse event in 85 FDA reports for CEFUROXIME SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY FIBROSIS accounts for approximately 1.7% of all adverse event reports for CEFUROXIME SODIUM, making it a notable side effect.
If you experience pulmonary fibrosis while taking CEFUROXIME SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.